Akebia Ther

Company Profile

Akebia Ther had its IPO on 2014-03-20 under the ticker symbol AKBA.

The company operates in the Healthcare sector and Biotechnology industry. Akebia Ther has a staff strength of 426 employees.

Stock update

Shares of Akebia Ther opened at $0.6 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $0.55 - $0.61, and closed at $0.56.

This is a -6.91% slip from the previous day's closing price.

A total volume of 1,191,398 shares were traded at the close of the day’s session.

In the last one week, shares of Akebia Ther have slipped by -15.69%.

Akebia Ther's Key Ratios

Akebia Ther has a market cap of $181.65 million, indicating a price to book ratio of 4.1167 and a price to sales ratio of 0.2809.

In the last 12-months Akebia Ther’s revenue was $297.03 million with a gross profit of $-17922000 and an EBITDA of $-67984000. The EBITDA ratio measures Akebia Ther's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Akebia Ther’s operating margin was -35.59% while its return on assets stood at -12.73% with a return of equity of -206.21%.

In Q3, Akebia Ther’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0.4%.

Akebia Ther’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.9 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Akebia Ther’s profitability.

Akebia Ther stock is trading at a EV to sales ratio of 0.0443 and a EV to EBITDA ratio of -0.13. Its price to sales ratio in the trailing 12-months stood at 0.2809.

Akebia Ther stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$435.89 million

Total Liabilities

$187.97 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Akebia Ther ended 2023 with $435.89 million in total assets and $0 in total liabilities. Its intangible assets were valued at $435.89 million while shareholder equity stood at $13.85 million.

Akebia Ther ended 2023 with $0 in deferred long-term liabilities, $187.97 million in other current liabilities, 2000.00 in common stock, $-1545361000.00 in retained earnings and $55.05 million in goodwill. Its cash balance stood at $144.76 million and cash and short-term investments were $144.76 million. The company’s total short-term debt was $70,207,000 while long-term debt stood at $0.

Akebia Ther’s total current assets stands at $237.51 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $23.09 million compared to accounts payable of $19.71 million and inventory worth $40.04 million.

In 2023, Akebia Ther's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Akebia Ther paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$0.56

52-Week High

$2.86

52-Week Low

$0.241

Analyst Target Price

$1.63

Akebia Ther stock is currently trading at $0.56 per share. It touched a 52-week high of $2.86 and a 52-week low of $2.86. Analysts tracking the stock have a 12-month average target price of $1.63.

Its 50-day moving average was $0.79 and 200-day moving average was $0.48 The short ratio stood at 1.72 indicating a short percent outstanding of 0%.

Around 127.9% of the company’s stock are held by insiders while 2923% are held by institutions.